Menu
Related Investments
Related Team

Arlington Capital Partners Announces Majority Investment in Grand River Aseptic Manufacturing

WASHINGTON, DC, November 14, 2017 – Arlington Capital Partners (“Arlington”), a Washington, DC-area private equity firm, today announced a majority investment in Grand River Aseptic Manufacturing (“GRAM” or the “Company”). Based in Grand Rapids, MI, GRAM is a leading contract, development and manufacturing organization (“CDMO”) focused on the development, manufacture and finishing of parenteral pharmaceuticals. GRAM focuses on partnering with its pharmaceutical and biopharmaceutical customers to provide full life cycle aseptic solutions from development through commercialization.

Matt Altman, a Managing Partner at Arlington, said, “Arlington is excited to partner with the GRAM team to continue building a world-class aseptic CDMO. The Company’s broad manufacturing experience and exemplary quality record provide an ideal platform from which to pursue the numerous growth initiatives we have collectively identified within the large and growing aseptic manufacturing market.  Our investment in GRAM continues Arlington’s history of building differentiated pharma services providers in partnership with leading management teams.”

“With the healthcare network, strategic vision and capital that Arlington brings to GRAM, we look forward to expanding our offerings and better serving our growing client base,” commented Tom Ross, CEO of GRAM. “Arlington has a strong track record of investing in pharmaceutical services and shares our vision for expanding GRAM’s capacity and capabilities with a focus on putting quality first.”

Malcolm Little, a Principal at Arlington, said, “The additional capacity made available by Arlington’s investment will position GRAM to continue capitalizing on the rising demand for parenteral development and manufacturing services driven by growth in the underlying biologic and generic injectables markets.  Rising regulatory pressures and continued consolidation have made independent aseptic manufacturing platforms, like GRAM, increasingly scarce and valuable.”

 

About Arlington Capital Partners

Arlington Capital Partners is a Washington, D.C.-area private equity firm that has managed $2.2 billion of committed capital via four investment funds, including Arlington’s fourth and most recent $700 million fund. Arlington is focused on middle market investment opportunities in growth industries, including: healthcare, aerospace/defense, government services and technology, and business services and software. The firm’s professionals and network have a unique combination of operating and private equity experience that enable Arlington to be a value-added investor. Arlington invests in companies in partnership with high quality management teams that are motivated to establish and/or advance their Company’s position as leading competitors in their field.   www.arlingtoncap.com

About Grand River Aseptic Manufacturing

Grand River Aseptic Manufacturing, a parenteral contract development and manufacturing organization, delivers customized solutions to meet clients’ fill and finish needs from development through commercialization. With capabilities for biologics as well as controlled substances, GRAM’s expert project managers and modern facilities support pharmaceutical development and cGMP manufacturing, analytical testing and regulatory filing. www.grandriverasepticmfg.com

 

Contact:

Matthew Altman

Arlington Capital Partners

5425 Wisconsin Avenue, Suite 200

Chevy Chase, MD 20815

(202) 337-7500

SOURCE: Arlington Capital Partners